Press release
Rivaroxaban Market Insights – Stop the Clot
Rivaroxaban is a Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) that is marketed as Xarelto. Anticoagulant medicines are potent therapeutic agents used in the prevention or treatment of serious illnesses and potentially life-threatening conditions associated with blood coagulation. Rivaroxaban was discovered by Bayer and is being jointly developed with Janssen Research & Development, LLC. Xarelto is approved for indications such as stroke prevention in non-valvular atrial fibrillation, pulmonary embolism, deep vein thrombosis, prevention of recurrent venous thromboembolism (VTE), prevention of VTE after elective hip and knee replacement surgery, and secondary prevention after acute coronary syndrome.In September 2008, the drug received CE approval for venous thromboembolism in adults undergoing knee and hip replacement surgeries and in 2011, it was approved by the U.S. Food and Drug Administration (FDA) for the same indication. Xarelto is approved in over 130 countries by respective regulatory bodies.
The global rivaroxaban market size is estimated to be valued at US$ 5,653 million in 2017 and is expected to witness a CAGR of 1.5% over the forecast period (2018 – 2026) on account of patent expiry during the forecast period.
Request For Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1962
As an anti-coagulant drug is intended to be used for the prevention and treatment of embolism and non-hemorrhagic stroke, increasing incidences of such medical conditions are expected to boost the rivaroxaban market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC) data of 2015, around 900,000 people are expected to be affected by venous thromboembolism each year in the U.S. Furthermore, the number of affected individuals are expected to increase by around 5% to 8% in the U.S., owing to several genetic risk factors such as condition known as inherited thrombophilia.
Moreover, endeavor to use the drug for additional indication is expected to support the market growth. For instance, Swiss Paraplegic Centre Nottwil was investigating the drug for cervical spinal cord injury, which is in phase 4 clinical trial as on December 2017. Furthermore, Onze Lieve Vrouw Hospital and AZ Sint-Jan AV are conducting clinical trial of 10 mg rivaroxaban for the indication of chronic renal failure. Another major factor negatively affecting the rivaroxaban market growth is patent expiration of the drug Xarelto. Patent expiration leads to the manufacturing of generic drugs, which can be leveraged by the generic manufactures. The availability of generic drugs is expected to lower the treatment cost making it affordable to a wider class of individuals.
Dreadful injuries caused due to Xarelto, has led the company face many legal issues in the U.S. market. For instance, as of January 30, 2018, Bayer Group had been served in the U.S. with around 22,000 claims of Xarelto for personal injuries from the use of Xarelto, which includes cerebral, gastrointestinal or other bleeding and death causes. On clearance of the claims, the market of the product is expected to be affected in terms of revenue.
Rivaroxaban Market Regional Outlook
On the basis of region, the global rivaroxaban market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is holding dominant position in the global rivaroxaban market, owing to high product sales coupled with high cost of the drug. For instance, the treatment cost for rivaroxaban is around US$ 450-500 per month and around 45% of the market revenue generated in 2017 was from the U.S. market. Moreover, according to an article published in the ‘Journal of The American Heart Association’, 2018, a hospital-based survey suggested the global burden of disability-adjusted life-years from venous thromboembolism to be 7.6 per 100,000 person-years. The high rate of mortality associated with venous thromboembolism increases the demand for drugs such as rivaroxaban.
Key players in the global rivaroxaban market
Major players operating in the global rivaroxaban market include Janssen Pharmaceuticals Inc. and Bayer AG.
Market players strategize to strengthen their foot hold in the market in spite of high cost by implementing cost-effective treatment schemes. For instance, Janssen Pharmaceuticals offer Xarelto manufacturer coupon or patient assistance program to lower the cost of the drug.
Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1962
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rivaroxaban Market Insights – Stop the Clot here
News-ID: 1711759 • Views: …
More Releases from Coherent Market Insights

Residential Roofing Market In-depth Insights, Business Opportunities and top com …
𝐓𝐡𝐞 𝐑𝐞𝐬𝐢𝐝𝐞𝐧𝐭𝐢𝐚𝐥 𝐑𝐨𝐨𝐟𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟏𝟏.𝟖𝟖 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟓 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝐔𝐒𝐃 𝟏𝟓.𝟖𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐.
The "Residential Roofing Market Report" is the result of extensive research and analysis conducted by our team of experienced market researchers through -
» 70% efforts of Primary Research
» 15% efforts of Secondary Research
» 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors,…

Laminating Adhesive Market Deep Research Report with Forecast by 2032 | Henkel A …
𝐓𝐡𝐞 𝐋𝐚𝐦𝐢𝐧𝐚𝐭𝐢𝐧𝐠 𝐀𝐝𝐡𝐞𝐬𝐢𝐯𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟒.𝟐𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟓 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝐔𝐒𝐃 𝟓.𝟖𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐.
The "Laminating Adhesive Market Report" is the result of extensive research and analysis conducted by our team of experienced market researchers through -
» 70% efforts of Primary Research
» 15% efforts of Secondary Research
» 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics…

Consumer Battery Market Is Booming Worldwide 2025-2032 | Toshiba, Panasonic, Sam …
Consumer Battery Market Analysis - 2025-2032:
Coherent Market Insights has released a new report titled "Consumer Battery Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032 (Version 2025)." This report provides an in-depth analysis of the Consumer Battery industry, featuring insights on market trends and performance. It also includes a thorough examination of competitors, regional dynamics, and the latest advancements within the market.
Coverage of the Consumer Battery Market:
The report provides…

Ready-to-Use Film Coating Market Booming Growth: Future Trends, Demand, and Dyna …
The global Ready-to-use Film Coating Market is expected to grow at 6.7% CAGR from 2025 to 2032.
𝐓𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐫𝐞𝐬𝐮𝐥𝐭 𝐨𝐟 𝐞𝐱𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐜𝐨𝐧𝐝𝐮𝐜𝐭𝐞𝐝 𝐛𝐲 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦 𝐨𝐟 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞𝐝 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited companies
Coverage of…
More Releases for Xarelto
Xarelto Market By Global Industry Report 2025 Top Manufacturers, Market Drivers, …
The market analysis is focused on primary and secondary data, collected through a systematic approach to research. The research methodology is described in accordance with the business experts and international research standards by professional market analysts. To draw the conclusion on the macroeconomic business climate, economic, political, and environmental regulations for the Xarelto Market are examined.
Download a Free Sample Copy of Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=4799020
The Xarelto market revenue was xx Million…
Rivaroxaban Market Development is Changing Business Needs? – A Progress Review …
Rivaroxaban Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players of the Rivaroxaban Industry.
Rivaroxaban Market report provides emerging opportunities in the market and the future impact of major drivers and challenges and, support decision makers in making cost-effective business decisions. One of…
Rivaroxaban Market 2019 | In-depth Analysis by Top Players Janssen Pharmaceutica …
As an anti-coagulant drug is intended to be used for the prevention and treatment of embolism and non-hemorrhagic stroke, increasing incidences of such medical conditions are expected to boost the rivaroxaban market growth over the forecast period.
For instance, according to the Centers for Disease Control and Prevention (CDC) data of 2015, around 900,000 people are expected to be affected by venous thromboembolism each year in the U.S. Furthermore, the number…
Rivaroxaban Market Industry Landscape And Acknowledgement with Top Players Janss …
The global rivaroxaban market size is estimated to be valued at US$ 5,653 million in 2017 and is expected to witness a CAGR of 1.5% over the forecast period (2018 – 2026) on account of patent expiry during the forecast period.
Rivaroxaban is a Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) that is marketed as Xarelto. Anticoagulant medicines are potent therapeutic agents used in the prevention or treatment of serious illnesses and…
Rivaroxaban Market - Global Outlook 2026 By TWO KEY Players Janssen Pharmaceutic …
Rivaroxaban is an oral anticoagulant, which was developed by Bayer and sold under the brand name Xarelto. The drug is indicated for the treatment of deep vein thrombosis prophylaxis or pulmonary embolism and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The drug is marketed by Bayer outside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals, Inc.
Xarelto is…
Rivaroxaban (Xarelto) Market 2018-2026: Share, Market Valuation, Sales by Region …
Rivaroxaban Market Report has been prepared based on an in-depth market analysis with inputs from experts. Global Rivaroxaban Market report 2018 covers the market landscape and its growth prospects over the coming years till 2026.
Free PDF Sample Brochure @ https://decisionmarketreports.com/request-sampleproductID=983367
Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength…